Ocular Therapeutix, Inc. (OCUL) Rises A lot Today, Is Now One of The Best Performer

July 11, 2018 - By Vivian Park

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Logo

The stock of Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a huge mover today! The stock increased 2.19% or $0.14 during the last trading session, reaching $6.52. About 510,614 shares traded or 55.72% up from the average. Ocular Therapeutix, Inc. (NASDAQ:OCUL) has declined 34.95% since July 11, 2017 and is downtrending. It has underperformed by 47.52% the S&P500.
The move comes after 5 months positive chart setup for the $243.07M company. It was reported on Jul, 11 by Barchart.com. We have $6.91 PT which if reached, will make NASDAQ:OCUL worth $14.58 million more.

Analysts await Ocular Therapeutix, Inc. (NASDAQ:OCUL) to report earnings on August, 14. They expect $-0.37 EPS, up 42.19 % or $0.27 from last year’s $-0.64 per share. After $-0.40 actual EPS reported by Ocular Therapeutix, Inc. for the previous quarter, Wall Street now forecasts -7.50 % EPS growth.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Ratings Coverage

Among 3 analysts covering Ocular Therapeutix (NASDAQ:OCUL), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ocular Therapeutix had 7 analyst reports since January 19, 2018 according to SRatingsIntel. The stock has “Buy” rating by Cantor Fitzgerald on Tuesday, May 8. The stock of Ocular Therapeutix, Inc. (NASDAQ:OCUL) earned “Buy” rating by Cantor Fitzgerald on Thursday, March 8. The firm has “Buy” rating by H.C. Wainwright given on Friday, March 9. H.C. Wainwright maintained it with “Buy” rating and $1000 target in Wednesday, May 9 report. As per Thursday, March 8, the company rating was maintained by BTIG Research. H.C. Wainwright maintained the shares of OCUL in report on Thursday, June 21 with “Buy” rating. The rating was upgraded by BTIG Research on Friday, January 19 to “Buy”.

More notable recent Ocular Therapeutix, Inc. (NASDAQ:OCUL) news were published by: Streetinsider.com which released: “Ocular Therapeutix (OCUL) PT Lowered to $13 at Cowen” on July 11, 2018, also Globenewswire.com with their article: “Report: Developing Opportunities within Mercantile Bank, Kindred Healthcare, Ocular Therapeutix, Roper …” published on June 22, 2018, Seekingalpha.com published: “Rounds Report: Ocular Rallied While Stellar FDA Due Diligence To Help Antibiotic Innovators” on June 13, 2018. More interesting news about Ocular Therapeutix, Inc. (NASDAQ:OCUL) were released by: Streetinsider.com and their article: “Ocular Therapeutix (OCUL) Announces NDA Resubmission of DEXTENZA” published on June 29, 2018 as well as Seekingalpha.com‘s news article titled: “Ocular Therapeutix (again) refiles US marketing application for Dextenza” with publication date: July 03, 2018.

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of ocular therapies using its Hydrogel technology. The company has market cap of $243.07 million. The Company’s product pipeline candidates utilize its platform to provide differentiated drug delivery solutions that are designed to reduce the complexity and burden of current drop or injection regimens by creating sustained release one-time or several-month dosage forms. It currently has negative earnings. The companyÂ’s lead product candidate, DEXTENZA 0.4 mg for intracanalicular use has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.